Luye Pharma Group Ltd.
🇨🇳China
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT04563936
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)Other: Neupro 4 mg / 24 Hr. Transdermal Patch
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04384666
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: LY01610( Irinotecan hydrochloride liposome injection )
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04381910
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China
A Study to Evaluate LY01011 and Xgeva® in Healthy Adults
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT04198636
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: LY01610 ( Irinotecan hydrochloride liposome injection )Drug: LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04088604
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: Placebo, extended-release microspheresDrug: LY03003 ( Rotigotine, extended-release microspheres)
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04045678
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, China
A Study of LY03003 in Patients With Early-stage Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: Placebo, extended-release microspheresDrug: Rotigotine, extended-release microspheres
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04044547
A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03844438
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Relative Bioavailability Food Effect Study of LY03005
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT03822065
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Phase 1
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo groupDrug: LY03005 extended-release tablets 40 mgDrug: LY03005 extended-release tablets 80 mg groupDrug: LY03005 extended-release tablets 120 mg groupDrug: LY03005 extended-release tablets 160 mg group
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT03785652
- Locations
- 🇨🇳
Approval Letter of Ethics Committee of The Sixth Hospital of Peking University, Haidian District,, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath